We're thrilled to shine a spotlight on our portfolio team, Urearetics, which is dedicated to driving innovation in healthcare! 👨🔬 Principal Investigator: Jeff Sands, MD (Emory) 💡A novel mechanism to treat uremic pericarditis and pericardial effusions in chronic kidney disease patients by inhibiting urea transport. Join us in celebrating their dedication to advancing medical research and improving patient outcomes!
Biolocity’s Post
More Relevant Posts
-
Getting ready for the 14th International Congress on Autoimmunity in Ljubljana, where we'll have a great representation of the Werfen Autoimmunity R&D team! Hope to see you at our industry session where some of the hot topics in autoimmune biomarkers will be discussed. #precisionmedicine #autoimmunity #biomarkers #autoantibodies
Are you coming to the 14th International Congress on Autoimmunity in Ljubljana, Slovenia? Be sure to visit us on booth # 1 and attend our industry session 💡“From Discovery to Clinical Practice: The Rise of Game-changing Autoimmune Biomarkers”. Scroll right for more details. We’re looking forward to seeing you there! #ICA2024 #Autoimmunity #Werfen #PoweringPatientCare #SpecializedDiagnostics
-
Enjoyed this discussion with Patricia Roselle about how Velocity Clinical Research, Inc. and Sanofi are putting patients first in clinical research. Much more to come from this collaboration. Thanks Jimmy Bechtel, MBA!
In this episode, Nick Spittal from Velocity Clinical Research, Inc. and Patricia Roselle with Sanofi celebrate Velocity's win of the 2023 Excellence in Patient Centricity Award. Hear insights from Velocity and Sanofi on the importance of patient-centricity and the initiatives that led to this award. Plus, we'll explore the future goals of both organizations in advancing clinical research with a patient-focused approach. ⇢ https://lnkd.in/dEu6-pM
-
-
Want to see real-life examples of Drug Repurposing in action? Explore the REMEDi4ALL case studies, each one is designed by experts to tell the story of #DrugRepurposing in a different disease. Learn about academic research, industry collaborations, cutting-edge clinical trial design and patient engagement as well as barriers facing drug repurposing. 🔍 Explore the REMEDi4ALL case studies here: https://lnkd.in/e2wKAb-f
-
-
Amazing news coming out of the Metrodora Foundation. The combination of foundational research, well characterized data and an engaged patient population will help us to better understand complex diseases impacting the nervous and immune systems. This would not be possible without the dedicated team at the Metrodora Institute led by Fidji Simo, John Wirthlin, Rohit Gupta, Amy Rochlin among many others. For me, Metrodora represents the next big step in health data utilization for drug development - building off my experiences at Medidata Solutions, Flatiron Health, Verana Health and Instem. With exciting technical advances in creating multi-modal Real World datasets, we should be seeing an exciting next wave of progress in understanding these complex diseases. https://lnkd.in/gQYMjnqq
-
Are you coming to the 14th International Congress on Autoimmunity in Ljubljana, Slovenia? Be sure to visit us on booth # 1 and attend our industry session 💡“From Discovery to Clinical Practice: The Rise of Game-changing Autoimmune Biomarkers”. Scroll right for more details. We’re looking forward to seeing you there! #ICA2024 #Autoimmunity #Werfen #PoweringPatientCare #SpecializedDiagnostics
-
Register below to learn more about the emerging important role of methylation-based ctDNA testing applications in MRD and response monitoring!
Join us for an upcoming online panel discussion focused on the transformative role of methylation-based ctDNA testing for minimal residual disease and response monitoring in clinical trials. Industry leaders Minakshi Guha, Jonathan Beer, Diana Merino Vega, and our VP of global scientific affairs Kimberly Banks will explore how liquid biopsy testing can accelerate drug development by enhancing patient enrollment, providing early therapy response monitoring, and expediting study evaluation. Register today: https://bit.ly/3YIeU2H 📅 Date: November 19 🕦 Time: 12:00pm ET
-
-
🌟 Today, Anton Ussi, CEO of EATRIS and Steering Group member of Together for Rare Diseases, is sharing how our partnership is making a difference! 🌟 🔬 Anton Ussi showcases the pivotal role of EATRIS (European Infrastructure for Translational Medicine) in bridging the gap between scientific breakthroughs and tangible medical advancements. The pan-European research infrastructure serves as a catalyst for transforming discoveries into impactful treatments. 🤝 Together, we are determined to unlock new avenues for partnerships. Let's join forces to make a difference in rare disease treatment and patient care! Watch the video below to find out more on the transformative potential of our collaboration 👇 #EATRIS #Together4RareDiseases #RareDisease #TranslationalMedicine
-
How can Worldwide support your metabolic dysfunction studies? Discover our full suite of MASH/MALD clinical development services in our fact sheet, from our core lab partnerships to global operational expertise: https://ow.ly/VyN550SwaQP
MASH/MASLD Clinical Development at Worldwide
worldwide.com
-
A proven healthcare strategist with demonstrated fiscal and operational excellence in both traditional and nontraditional sectors.
How can the #platform business model transform the way #healthcare is delivered? Listen to Bobbi Pritt and William Morice II, MD, PhD, to learn more.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Bill Morice, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the platform business model and how it’s being used in the healthcare industry to drive innovation and reimagine how care is provided. https://bit.ly/4chgCvN
-
Delighted to announce our collaboration with Merz Therapeutics with the launch of iFlexo, a personalized digital solution aimed at enhancing rehabilitation for people with post-stroke spasticity. iFlexo, developed and operated on S3 Connected Health’s digital health platform Affinial provides targeted exercises and rehabilitation programs specifically aimed at improving mobility for those with mild to moderate spasticity. By offering guided routines, iFlexo aims to help stroke survivors regain independence and improve their overall quality of life. Learn more about the launch of iFlexo here: 👉 https://lnkd.in/eWTuRZ_z
-
